Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Change in Acquisitions & Divestments (2023 - 2024)

Oncology Institute (TOI) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $10.0 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Change in Acquisitions & Divestments rose 16.62% year-over-year to $10.0 million, compared with a TTM value of $10.0 million through Jun 2025, down 83.64%, and an annual FY2024 reading of $50.0 million, down 38.47% over the prior year.
  • Change in Acquisitions & Divestments was $10.0 million for Q3 2024 at Oncology Institute, down from $20.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $30.1 million in Q2 2023 and bottomed at $8.6 million in Q3 2023.